- Home
- APDN vs DRMA Comparison
APDN vs DRMA Comparison
Compare APDN & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APDN
- DRMA
- Stock Information
- Founded
- APDN 1983
- DRMA 2014
- Country
- APDN United States
- DRMA United States
- Employees
- APDN N/A
- DRMA N/A
- Industry
- APDN Other Consumer Services
- DRMA Biotechnology: Pharmaceutical Preparations
- Sector
- APDN Consumer Discretionary
- DRMA Health Care
- Exchange
- APDN Nasdaq
- DRMA Nasdaq
- Market Cap
- APDN 4.2M
- DRMA 4.5M
- IPO Year
- APDN N/A
- DRMA 2021
- Fundamental
- Price
- APDN $4.98
- DRMA $0.60
- Analyst Decision
- APDN
- DRMA Strong Buy
- Analyst Count
- APDN 0
- DRMA 1
- Target Price
- APDN N/A
- DRMA $3.00
- AVG Volume (30 Days)
- APDN 129.1K
- DRMA 94.5K
- Earning Date
- APDN 08-07-2025
- DRMA 08-06-2025
- Dividend Yield
- APDN N/A
- DRMA N/A
- EPS Growth
- APDN N/A
- DRMA N/A
- EPS
- APDN N/A
- DRMA N/A
- Revenue
- APDN $3,790,616.00
- DRMA N/A
- Revenue This Year
- APDN $57.08
- DRMA N/A
- Revenue Next Year
- APDN $40.00
- DRMA N/A
- P/E Ratio
- APDN N/A
- DRMA N/A
- Revenue Growth
- APDN N/A
- DRMA N/A
- 52 Week Low
- APDN $4.37
- DRMA $0.57
- 52 Week High
- APDN $2,655.00
- DRMA $5.00
- Technical
- Relative Strength Index (RSI)
- APDN 29.27
- DRMA 29.24
- Support Level
- APDN $4.44
- DRMA $0.57
- Resistance Level
- APDN $5.50
- DRMA $0.63
- Average True Range (ATR)
- APDN 0.56
- DRMA 0.04
- MACD
- APDN 0.46
- DRMA -0.01
- Stochastic Oscillator
- APDN 7.42
- DRMA 11.55
About APDN Applied DNA Sciences Inc.
Applied DNA Sciences Inc is a biotechnology company developing and commercializing technologies to produce and detect deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The company operates in three business segments- Therapeutic DNA Production Services, MDx Testing Services, and DNA Tagging and Security Products and Services. It generates majority of its revenue from the MDx Testing Services which is involved in performing and developing clinical molecular diagnostic and genetic tests and clinical laboratory testing services. The company provides its products and services under the brand of Applied DNA Sciences, SigNature molecular tags, SigNature T molecular tags, fiberTyping, SigNify and others.
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.